Xencor, Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
31
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Nov 14 to 26, 2026 · next Nov 14
- 3 fees due Dec 11 to 23, 2026 · next Dec 11
- 2 fees due Jan 2 to 14, 2027 · next Jan 2
- 3 fees due Feb 8 to 28, 2027 · next Feb 8
- 1 fee due Apr 1, 2027The maintenance fee for Trispecific antibodies (US 10,428,155) comes due Apr 1, 2027. Unpaid by Oct 1, 2027, it lapses early.
- 3 fees due May 12 to 26, 2027 · next May 12
- 5 fees due Jun 10 to 30, 2027 · next Jun 10
- 4 fees due Jul 2 to 28, 2027 · next Jul 2
- 3 fees due Aug 4 to 23, 2027 · next Aug 4
- 4 fees due Sep 5 to 19, 2027 · next Sep 5
- 1 fee due Oct 2, 2027The maintenance fee for Heterodimeric Antibodies That Bind CD3 and Tumor Antigens (US 11,945,880) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 5 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,084,582 | Optimized anti-CD20 monoclonal antibodies having Fc variants In force · From the USPTO record | In force | From the USPTO record | |
| US 9,200,079 | Fc variants with altered binding to FcRn In force · Medium confidence | In force | Medium confidence | |
| US 9,040,041 | Modified FC molecules In force · From the USPTO record | In force | From the USPTO record | |
| US 10,336,818 | Fc VARIANTS WITH ALTERED BINDING TO FcRn In force · Medium confidence | In force | Medium confidence | |
| US 8,338,574 | FC variants with altered binding to FCRN In force · From the USPTO record | In force | From the USPTO record | |
| US 8,937,158 | Fc variants with increased affinity for FcγRIIc In force · From the USPTO record | In force | From the USPTO record | |
| US 10,626,182 | Optimized antibodies that target CD19 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,260,523 | Methods and compositions for inhibiting CD32b expressing cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,079,960 | Methods and compositions for inhibiting CD32B expressing cells In force · From the USPTO record | In force | From the USPTO record | |
| US 11,434,295 | Methods and compositions for inhibiting CD32B expressing cells In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 147: 4 patents in force now held by others · 22 lapsed for an unpaid fee · 59 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
32 pending · 42 abandoned · 143 no status recorded